Oncopeptides: CHMP Recommends Third-Line Treatment Extension - Redeye

Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion recommending an expansion of Pepaxti's (melflufen) label, in combination with dexamethasone, from fourth-line to third-line multiple myeloma. The opinion now goes to the European Commission for a final decision.

Länk till analysen i sin helhet: https://www.redeye.se/research/1185526/oncopeptides-chmp-recommends-third-line-treatment-extension?utm_source=finwire&utm_medium=RSS